Grant: Engage Grants Program
Queen's University
$25,000.00
Scaffold surface modification and characterization for tissue engineering
EF 2012-13
Résumé
Octane Biotech Inc.is developing a new orthopedic technology that incorporates the patient's own cells in a
fully resorbable synthetic calcium phosphate graft material. The manufactured bone graft will be engineered to
be comparable in mechanical and physiological performance to that of bone harvested from the patient. The
novel approach to this bone graft technology is to first expand the cells to clinically effective numbers in a
non-implantable proliferation scaffold, release the cells from this first scaffold in order to analyze the cells for
number and phenotype, and then re-seed cells on an implantable SkeliteTM differentiation scaffold to drive the
formation of bone cells. Two specific problems will be addressed; 1) the hydrophobicity of the proliferation
scaffold and 2) the inconsistent phase composition of the differentiation scaffold. The proliferation scaffold has
a high surface area, allows for nutrient and metabolic transfer and maintains its structure within the cell media,
but restrains cell proliferation due to its inherent hydrophobicity. This project will assess the ability of plasma
oxidation to decrease the hydrophobicity of the scaffold. The inconsistent phase composition of the
differentiation scaffold will be investigated by characterizing and assessing the variability of the initial
reagents. By overcoming these two technical hurdles, Octane Medical Group will be able to produce a cellular
bone graft material and initiate pre-clinical testing.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
435119-2012
Name nom
Rutter, Allison
Department département
Environmental Studies, School of
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Scaffold surface modification and characterization for tissue engineering
Keyword
NSERC
Application summary
Octane Biotech Inc.is developing a new orthopedic technology that incorporates the patient's own cells in a
fully resorbable synthetic calcium phosphate graft material. The manufactured bone graft will be engineered to
be comparable in mechanical and physiological performance to that of bone harvested from the patient. The
novel approach to this bone graft technology is to first expand the cells to clinically effective numbers in a
non-implantable proliferation scaffold, release the cells from this first scaffold in order to analyze the cells for
number and phenotype, and then re-seed cells on an implantable SkeliteTM differentiation scaffold to drive the
formation of bone cells. Two specific problems will be addressed; 1) the hydrophobicity of the proliferation
scaffold and 2) the inconsistent phase composition of the differentiation scaffold. The proliferation scaffold has
a high surface area, allows for nutrient and metabolic transfer and maintains its structure within the cell media,
but restrains cell proliferation due to its inherent hydrophobicity. This project will assess the ability of plasma
oxidation to decrease the hydrophobicity of the scaffold. The inconsistent phase composition of the
differentiation scaffold will be investigated by characterizing and assessing the variability of the initial
reagents. By overcoming these two technical hurdles, Octane Medical Group will be able to produce a cellular
bone graft material and initiate pre-clinical testing.